| Drug Type Small molecule drug | 
| Synonyms Fenofibrate/pitavastatin, HL-PIF, Livasupril + [4] | 
| Target | 
| Action inhibitors, agonists | 
| Mechanism HMG-CoA reductase inhibitors(HMG-CoA reductase inhibitors), PPARα agonists(Peroxisome proliferator-activated receptor α agonists) | 
| Therapeutic Areas | 
| Active Indication | 
| Inactive Indication | 
| Originator Organization | 
| Active Organization | 
| Inactive Organization- | 
| License Organization- | 
| Drug Highest PhaseApproved | 
| First Approval Date South Korea (03 Apr 2019),  | 
| Regulation- | 
| Molecular FormulaC25H24CaFNO4 | 
| InChIKeyAMUDYCAFPCQTAZ-NRFPMOEYSA-N | 
| CAS Registry147526-32-7 | 
| Indication | Country/Location | Organization | Date | 
|---|---|---|---|
| Coronary Disease | South Korea  | 30 Apr 2025 | |
| Hyperlipidemias | South Korea  | 03 Apr 2019 | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Complex dyslipidemia | Phase 3 | - | 01 Nov 2015 | 





